{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:30:49Z","timestamp":1787772649817,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Here we report a case of a 34-year-old patient with psoriasis who developed uveitis induced by adalimumab. After receiving two subcutaneous injections of adalimumab, the patient suffered from a sudden onset of ocular pain and blurred vision in her left eye, which was diagnosed with acute anterior uveitis. Adalimumab therapy was discontinued and the patient was hospitalised for the treatment of acute anterior uveitis with systemic corticosteroids. This paradoxical adverse event was alleviated after timely interventions and went into remission during a 6-month follow-up period. To the best of our knowledge, this is the first case of uveitis occurring in patients with psoriasis under adalimumab treatment. It indicates that paradoxical uveitis, although rare, is one of the adverse events of adalimumab therapy. Early recognition and prompt intervention would lead to a good outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_366_21","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:20:03Z","timestamp":1724952003000},"page":"207","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Uveitis Occurring in a Patient with Psoriasis during Adalimumab Therapy"],"prefix":"10.4103","volume":"67","author":[{"given":"Qiaoli","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-51-20240829","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"R2-51-20240829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"R3-51-20240829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2040622318772705","article-title":"Safety and tolerability of adalimumab for the treatment of psoriasis: A review summarizing 15 years of real-life experience","volume":"9","author":"Sator","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"R4-51-20240829","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: A review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R5-51-20240829","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"Perez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"R6-51-20240829","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","article-title":"Adalimumab-associated optic neuritis","volume":"244","author":"Chung","year":"2006","journal-title":"J Neurol Sci"},{"key":"R7-51-20240829","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s10067-017-3712-8","article-title":"Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: Similarities and differences","volume":"36","author":"Favalli","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R8-51-20240829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R9-51-20240829","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/09273948.2011.644383","article-title":"Drug-induced inflammation in patients on TNFalpha inhibitors","volume":"20","author":"Cunningham ET","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R10-51-20240829","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/09273948.2011.623213","article-title":"Sarcoid-related uveitis occurring during adalimumab therapy","volume":"20","author":"Seve","year":"2012","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_366_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:07:21Z","timestamp":1787771241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_366_21"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_366_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}